title: Pneumocystis and Pneumocystosis: first meeting of experts from Latin-American and Portuguese-speaking countries - a mini-review.
abstract: The Pneumocystis and Pneumocystosis: first meeting of experts from Latin-American and Portuguese-speaking countries was held in Lisbon, Portugal, on 24-26 October 2013. A total of 20 speakers from Latin America, Africa and Europe participated in the meeting. The epidemiological studies presented in this meeting begin to change the misconception that since the AIDS epidemic, Pneumocystis pneumonia (PcP) has become an infrequent disease, showing that today PcP remains a major opportunistic infection in HIV-infected patients in both developed and developing countries and an emerging problem in immunocompromised patients without HIV infection worldwide. PcP management remains a challenge. Right now, the combination of caspofungin and trimethoprim-sulfamethoxazole (TMP-SMX) is a promising therapeutic approach that needs to be assessed in controlled clinical trials.
authors.affiliation: Grupo de Protozoários Oportunistas/VIH e Outros Protozoários, Unidade de Parasitologia Médica, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal.
authors.forename: Francisco
authors.initials: F
authors.lastname: Esteves
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Medrano
authors.forename: Yaxsier
authors.initials: Y
authors.lastname: de Armas
authors.forename: Gustavo
authors.initials: G
authors.lastname: Wissmann
authors.forename: Enrique J
authors.initials: EJ
authors.lastname: Calderón
authors.forename: Olga
authors.initials: O
authors.lastname: Matos
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology / Q000821:virology; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000077336:Caspofungin; D019049:Developed Countries; D003906:Developing Countries; D054714:Echinocandins / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007843:Latin America; D055666:Lipopeptides; D045363:Pneumocystis carinii / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology / Q000821:virology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D054714:Echinocandins; D055666:Lipopeptides; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000077336:Caspofungin